- Home
- THFF vs KROS Comparison
THFF vs KROS Comparison
Compare THFF & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THFF
- KROS
- Stock Information
- Founded
- THFF 1984
- KROS 2015
- Country
- THFF United States
- KROS United States
- Employees
- THFF N/A
- KROS N/A
- Industry
- THFF Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- THFF Finance
- KROS Health Care
- Exchange
- THFF Nasdaq
- KROS Nasdaq
- Market Cap
- THFF 686.6M
- KROS 565.0M
- IPO Year
- THFF N/A
- KROS 2020
- Fundamental
- Price
- THFF $54.37
- KROS $15.40
- Analyst Decision
- THFF Buy
- KROS Buy
- Analyst Count
- THFF 3
- KROS 14
- Target Price
- THFF $59.50
- KROS $20.56
- AVG Volume (30 Days)
- THFF 67.5K
- KROS 919.9K
- Earning Date
- THFF 10-24-2025
- KROS 11-05-2025
- Dividend Yield
- THFF 3.76%
- KROS N/A
- EPS Growth
- THFF 21.43
- KROS N/A
- EPS
- THFF 5.24
- KROS 0.47
- Revenue
- THFF $230,446,000.00
- KROS $232,844,000.00
- Revenue This Year
- THFF $30.73
- KROS $6,657.47
- Revenue Next Year
- THFF $2.82
- KROS N/A
- P/E Ratio
- THFF $10.35
- KROS $33.11
- Revenue Growth
- THFF 19.59
- KROS 85820.30
- 52 Week Low
- THFF $41.91
- KROS $9.12
- 52 Week High
- THFF $63.04
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- THFF 47.84
- KROS 50.90
- Support Level
- THFF $51.21
- KROS $13.60
- Resistance Level
- THFF $55.01
- KROS $15.46
- Average True Range (ATR)
- THFF 1.39
- KROS 0.75
- MACD
- THFF -0.02
- KROS -0.11
- Stochastic Oscillator
- THFF 76.70
- KROS 60.61
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.